Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Aerosol containment device design considerations and performance evaluation metrics

Rachael M. Jones, PhD a,b,⁎, Niles Andrus, MS a, Thomas Dominguez, MS a, Jeremy Biggs, MD a, Brian Hansen, MS a, Frank A. Drews, PhD c

a Department of Family and Preventive Medicine, Spencer Fox Eccles School of Medicine, University of Utah, United States of America
b Department of Environmental Health Sciences, Fielding School of Public Health, University of California, Los Angeles, United States of America
c Department of Psychology, College of Social and Behavioral Science, University of Utah, United States of America

Abstract

Background: Spurred by the Coronavirus infectious disease 2019 pandemic, aerosol containment devices (ACDs) were developed to capture infectious respiratory aerosols generated by patients at their source. Prior reviews indicated that such devices had low evidence of effectiveness, but did not address how ACDs should be evaluated, how well they should perform, nor have clearly defined performance standards. Towards developing design criteria for ACDs, two questions were posed: 1) What characteristics have guided the design of ACDs? 2) How have these characteristics been evaluated?

Methods: A scoping review was performed consistent with PRISMA guidelines. Data were extracted with respect to general study information, intended use of the device, device design characteristics and evaluation.

Results: Fifty-four articles were included. Evaluation was most commonly performed with respect to device aerosol containment (n = 31, 61%), with only 5 (9%), 3 (6%) and 8 (15%) formally assessing providing experience, patient experience and procedure impact, respectively. Nearly all of the studies that explored provider experience and procedure impact studied intubation. Few studies provided a priori performance criteria for any evaluation metric, or referenced any external guidelines by which to benchmark performance.

Conclusion: With respect to aerosol containment, ACDs should reduce exposure among HCP with the device compared with the absence of the device, and provide ≥90% reduction in respirable aerosols, equivalent in performance to N95 filtering facepiece respirators, if the goal is to reduce reliance on personal protective equipment. The ACD should not increase awkward or uncomfortable postures, or adversely impact biomechanics of the procedure itself as this could have implications for procedure outcomes. A variety of standardized instruments exist to assess the experience of patients and healthcare personnel. Integration of ACDs into routine clinical practice requires rigorous studies of aerosol containment and the user experience.

© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Patients with respiratory infectious diseases, including pulmonary tuberculosis, influenza and Coronavirus Infectious Disease 2019 (COVID-19) can emit infectious aerosols into the environment, resulting in increased risk of disease transmission to susceptible patients and healthcare personnel (HCP). The primary strategies used in healthcare facilities to prevent the transmission of respiratory infectious diseases from patients are airborne precautions, consisting of a combination of the use of negative pressure airborne isolation rooms (AIIRs), use of surgical masks by patients, and the use of surgical masks or respirators by HCP; and droplet precautions, which consist of use of surgical masks by HCP [1]. In the first years of the COVID-19 pandemic, COVID-19 cases overwhelmed the available number of AIIRs, and resulted in shortages of respirators and surgical masks. These circumstances led to rapid innovation in infectious disease prevention strategies, including research into novel designs of personal protective equipment (PPE) to be worn by HCP [2], as well as devices intended to capture infectious...
aerosols generated by patients and prevent pathogens from entering the environment.

Out of necessity, the development of aerosol containment devices (ACDs) during the COVID-19 pandemic has been rapid and widespread. For example, members of the University of Utah Center for Medical Innovation developed one such device for head-of-bed procedures like intubation and general respiratory aerosol containment patient transport, vent disconnection and noninvasive airway interventions [3]; this device was utilized in a number settings including the emergency department at University Hospital to reduce environmental contamination and the risk of HCP exposure. The broad adoption of ACDs is not particularly surprising because they offer a local control mechanism, and can be built at low cost using readily-available materials. Sorbello et al. [4] reviewed the literature through May 27, 2020 and found that while a wide variety of ACDs had been described, evidence for effectiveness of ACDs was lacking, with some studies suggesting the devices may hinder airway management. Saito and Asai [5] drew the same conclusions.

The goal of this review differs from prior reviews, in that the focus is on identifying a set of design criteria for ACDs with the purpose of guiding future device design and evaluation, and facilitating comparison between devices. That is, the review seeks to explore how ACDs should perform and how performance should be assessed. To achieve this goal, a literature review was performed guided by two questions: 1) What characteristics have guided the design ACDs? 2) How have these characteristics been evaluated? Findings from the literature review will be discussed in conjunction with best-practices for user-centered design to recommend design and evaluation criteria for current and future ACDs.

2. Methods

Consistent with PRISMA guidelines for scoping literature review performance and reporting, a multi-step approach was used that involved: forming the question, defining inclusion/exclusion criteria and search terms, selecting studies, and extracting data [6,7]. Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) was used to manage the review process. The primary research questions were: 1) What characteristics have guided the design ACDs? 2) How have these characteristics been evaluated? The devices of interest are those intended to contain aerosols generated from the airways or medical procedures involving the head and respiratory tract. Two databases were identified for the literature search: PubMed and Web of Science. PubMed comprehensively covers the medical literature, and the Web of Science comprehensively covers the aerosol science literature. The search strategy shown in Table 1 was implemented on April 22, 2021, and was repeated on August 30, 2021 and May 15, 2022 to identify subsequently published articles. In the last search in Web of Science, the phrase “healthcare OR health care” was inadvertently omitted from the query, yielding a larger number of articles than in prior searches. Identified literature was exported into Covidence. Studies published prior to 2010 were excluded because ACDs have not historically been a research priority, and preliminary search strategy tests identified few articles to have been published on this topic prior to this date.

Table 1
Search strategy implemented in PubMed and Web of Science

| Connection | Terms |
|------------|-------|
| AND        | aerosol OR airway OR intubation OR particles |
| AND        | box OR tent OR drape OR barrier OR enclosure OR sheet |
| AND        | containment OR control |
| AND        | healthcare OR “health care” |
| NOT        | respiratory distress OR “noninvasive ventilation” OR “respiratory failure” OR “airway pressure” |
| NOT        | review |
| AND        | publication since 1/1/2010 |
| AND        | English language |

Titles and abstracts were independently reviewed by two of five investigators (BH, JB, RMJ, NA and TD) using a priori inclusion and exclusion criteria; disagreements were resolved through discussion. The inclusion criterion used was that the study describes the design or evaluation of a device intended to contain aerosols generated from the patient head and airways. Among the exclusion criteria were: 1) that an article is a review or commentary, 2) that the device is not intended to contain aerosols generated from the head or airways (e.g., for other sources of aerosols), 3) the device studied is intended for dental procedures, and 4) that the study is not about a device intended to contain aerosols, such as PPE for HCP. Full texts were screened by the two of five investigators (BH, JB, RMJ, NA and TD) using the inclusion and exclusion criteria, and differences in selection were resolved through discussion.

Consistent with the approach of a scoping review, included literature was not formally assessed for quality. A custom template was developed in Covidence for data extraction. Data extraction was organized into the following categories:

1. general study information, including study design and participant characteristics;
2. intended use of the device;
3. device design characteristics (e.g., structure type, materials, ventilation, etc.);
4. assessment of provider experience with the device (e.g., cognitive demands, posture and biomechanics, user perception);
5. assessment of device aerosol containment performance;
6. assessment of patient experience with the device, including with participants in experimental simulation setting; and
7. impact of device on the medical procedure or other intended use.

Categories 1–3 were selected to capture general information about the study and device, while categories 4–7 reflect components of user-centered design.

Study designs were classified as experimental simulation, field trials, or descriptive studies. Experimental simulation involved evaluation of the device under controlled conditions in the laboratory or patient care areas using task trainers or participants who were not actually receiving or delivering clinical care. Field trials involved use of the device with patients during clinical care, and included case reports. Descriptive studies only described the device.

For categories 4–7, assessments were considered to have been performed when their methods and results were formally described; otherwise, outcomes were classified as anecdotal. For example, a statement to the effect that providers said the device was easy to use was considered anecdotal unless the methods section identified the systematic use of a survey or interview to collect provider experiences and the results of this data collection are provided, including the number of participants and a descriptive summary of results.

3. Results

The literature searches identified 1144 articles, of which 117 were duplicates. Title and abstract screening excluded 962 articles, leaving 65 for full-text review; 54 articles were included in the review (Fig. 1). All included studies were published in 2020 or later. Thirty-three studies (61%) had corresponding authors from North America (Table S1). There were six studies (11%) that had corresponding authors from South Asia, and nine (17%) from East Asia; other studies had corresponding authors from Australia, Africa and Europe.

Table 2 summarizes the device types and device evaluation components of the included studies, by study design. The devices studied fall into four broad categories: 1) rigid box (R), which has rigid materials (e.g. acrylic sheets) forming the sides of the primary structure but may have drape on the side over the patient’s torso, 2) frame with drape (FD), which has a rigid or semi-rigid frame to which one or
more drapes were affixed, 3) drape only (D), which has one or more drapes attached to a piece of medical equipment (e.g., microscope) or laid across the patient’s body, and 4) masks (M), which were devices worn by the patient to contain aerosols (Table 2). Some studies evaluated more than one device design; two studies were by the same authors and evaluated the same design [8,9]. Experimental simulation was used in the majority of the reviewed studies (n = 35, 65%). Field trials were used in 24% of studies (n = 13). Eleven percent (n = 6) of studies consisted of a description of the device [10-14] only, and therefore are not discussed further. Supplementary Table 1 provides additional details about the device designs and study characteristics.

Four areas of device performance evaluations were identified a priori based on principles of user-centered design, including 1) provider experience with the device, 2) aerosol containment performance, 3) patient experience with the device and 4) impact of device on the medical procedure or other intended use. Table 2 provides an overview of which references performed evaluations in these four areas using formal or anecdotal methods, with latter involving statements reported by the authors in the absence of described structured data collection methods and formal result reporting. Evaluation was most commonly performed with respect to device aerosol containment (n = 33, 61%). Only five (9%) studies formally evaluated provider experience, while three (6%) evaluated patient experience. Eight (15%) studies evaluated the impact of the device on some aspect of the intended use, such as ability of providers to perform a medical procedure on a task trainer, or provide a medical procedure to a patient.

Seven of the studies that evaluated device impact on procedure performance studied adult intubation, while one studied endoscopy [15]. Three of the intubation studies assessed procedure performance in patients [16-18], while the others utilized an experimental simulation method with task trainers. Table 3 summarizes the performance metrics used in studies involving intubation procedures. Time to completion of intubation was the most commonly used metric. To assess the device’s impact on performance, two studies [11,14] used an a priori threshold (a larger than 10 s increase in time to intubation compared to intubation procedures without the device present as control condition) whereas one study [19] used a statistical test (noninferiority) as a decision criterion. Two studies measured ease of intubation using the Cormak-Lehane grading system [16,17], while other studies used Likert scales about perceived difficulty. Colman et al. [20] did not directly assess procedure performance, but identified through a simulation-based user-centered design approach a number of design factors with potential impact on procedure performance. Among these factors were device size and set-up requirements potentially delaying patient care, impeding positioning the device, or limiting the use of equipment inside the device. In the study about device impact on endoscopy, the outcomes were mean difference in procedure duration and image quality grade [15].

All five of the studies that evaluated provider experience with the device involved adult intubation as the procedure (Table 2). Colman et al. [20] evaluated provider experience using a facilitated debriefing session after simulation, and identified a number of design issues related to provider safety, including: loss of negative pressure when opening the device, tearing of device materials, and potential need to initiate procedure before device was in place. Other studies used investigator-developed surveys to assess provider experience, with the topics listed in Table 3. No studies assessed cognitive demands on providers, although Jen et al. [16] reported participant comments to the effect that the device increased cognitive demands during intubation. Further, no studies formally assessed posture nor biomechanics among participants using the devices, though related participant comments – both positive and negative – were noted in several studies [11,16,21-25]. One study reported anecdotally that the participating laryngoscopists noted glare from the device [19].

Patient experience with device use was assessed in three studies. Workman et al. [26] assessed patient satisfaction with wearing a ventilated mask during an ear, nose and throat (ENT) procedure on a 10-point Likert scale. Jen et al. [16] assessed patient perception of comfort and acceptability of a rigid device during intubation on a 5-point Likert scale. Puthenveettal et al. [17] assessed orodental injuries and hemodynamic variables among patients.
Among the 33 studies that performed aerosol containment, 19 (58%) involved ventilated devices and 14 (42%) involved unventilated devices (Table 4). In 61% of the studies, a procedure was always (n = 17) or sometimes (n = 3) performed or simulated by a participant acting as a HCP to some extent during the containment testing. Among the studies that visually assessed contamination on surfaces outside the device, all of the studies utilized fluorescent material as the tracer except for one study, which used spray paint [10]. Among the studies that visually assessed contamination on participants performing the procedure, all utilized fluorescent materials except for two studies, which used simulation experiments.

### Table 2

| Reference | Device Design | Device Ventilation | Target Patient Pop. | Target Procedure | Evaluation |
|-----------|---------------|--------------------|---------------------|------------------|------------|
| Babazade et al. [11] | D | None | AD | INT | Anec. | N | N | N |
| Fox et al. [14] | FD | Suction | AD | General | N | Anec. | N | N |
| Gupta et al. [42] | FD | Suction | AD | General | N | N | Anec. | N |
| Motara et al. [13] | R | None | AD | INT | Anec. | N | N | N |
| Rehm et al. [12] | D | None | AD | INT | N | N | N |
| Ueno et al. [52] | R | Suction | AD | General | N | N | N |
| Field Trials | | | | |
| Bianco et al. [53] | R | None | AD | INT | N | N | N |
| Chow et al. [27] | FD | Suction | AD | ENT Surg | N | Y | N | N |
| Das et al. [54] | D | Suction | AD | ENT Surg | N | N | N |
| Ghely et al. [55] | FD | Suction | AD | INT | Anec. | N | Anec. | N |
| Gonzales-Ciccarelli et al. [56] | FD | Suction | AD | ENT Surg | Anec. | N | N | N |
| Jen et al. [16] | R | None | AD | INT | Y | N | Y | Y |
| Leow et al. [57] | D | None | AD | Endoscopy | N | N | N | N |
| Luk et al. [58] | D | None | AD | INT | Anec. | Y | N | N |
| Nair et al. [59] | R | Suction | AD | ENT Surg | Anec. | N | N |
| Puthenveettil et al. [17] | R | None | AD | INT | N | N | Y | Y |
| Sen et al. [18] | R | Suction | PED | PED, RET | N | N | N |
| Workman et al. [26] | M | Suction | AD | Endoscopy | N | Y | Y |
| Yamamoto et al. [60] | R | None | AD | Bronchoscopy | N | N | N |

**TOTAL WITH ASSESSMENT (YES)**

- 5 (9%) 33 (61%) 3 (6%) 8 (15%)

1. R = Rigid box, RD = rigid box with drape, FD = frame with drape, D = drape only, and M = mask.
2. Suction refers to wall suction or portable suction device, including smoke evacuator, surgical waste management system or vacuum; Fan refers to use of a fan to remove air from the device via a duct, typically with filtration.
3. Population is AD (AD) or PED (PED) patients; Procedures include: Intubation/Extubation (INT), general containment or airway procedures, including patient transport (General); ear, nose and throat surgery such as mastoidectomy or tracheostomy (ENT Surg); nebulized drug therapy (NDT); high-flow oxygen nasal cannula (HFNC); and cardiopulmonary resuscitation (CPR).
Effect on movement \[21,64\]

Perception of comfort of device \[16\]

Ease of assembly \[64\]

Provider Experience Metrics

Perception of intubation difficulty \[16,17\]

Interest in using the device \[16,17\]

Effect on communication \[64\]

Effect on ability see what was required \[64\]

Effect on movement \[21,64\]

Ease of assembly \[64\]

Perception of improved safety \[64\]

Ease of use \[19,64\]

**Procedure Performance Metrics**

- Time to intubation X \[16,17,19,21,64\]
- Proportion of first-pass successful intubation (failed intubations) X \[16,17,21\]
- Number of intubation attempts X \[16\]
- Total time of airflow manipulation X \[16,19\]
- Intubation difficulty: Perceived X \[16,17,21\]
- Intubation difficulty: Cormak-Lehane Grading X \[16,17\]
- Proportion with airway loss X \[17\]
- Hemodynamic variables X \[16,17\]
- Patient Cough X \[17\]

**Patient Experience Metrics**

- Orodental injury to patient X \[17\]
- Perception of comfort of device X \[16\]
- Perception of acceptability of device X \[16\]

**Table 3**

| Metric | Objective | Subjective | Assess In Patients | Reference |
|--------|-----------|------------|--------------------|-----------|
| Procedure Performance Metrics | Time to intubation | X | | \[16,17,19,21,64\] |
| | Proportion of first-pass successful intubation (failed intubations) | X | | \[16,17,21\] |
| | Number of intubation attempts | X | | \[16\] |
| | Total time of airflow manipulation | X | | \[16,19\] |
| | Intubation difficulty: Perceived | X | | \[16,17,21\] |
| | Intubation difficulty: Cormak-Lehane Grading | X | | \[16,17\] |
| | Proportion with airway loss | X | | \[17\] |
| | Hemodynamic variables | X | | \[16,17\] |
| | Patient Cough | X | | \[17\] |
| Patient Experience Metrics | Orodental injury to patient | X | X | \[17\] |
| | Perception of comfort of device | X | X | \[16\] |
| | Perception of acceptability of device | X | X | \[16\] |
| Provider Experience Metrics | Perception of intubation difficulty | X | | \[16,17,21\] |
| | Interest in using the device | X | | \[16,17,21\] |
| | Effect on communication | X | X | \[64\] |
| | Effect on ability see what was required | X | | \[64\] |
| | Effect on movement | X | | \[21,64\] |
| | Ease of assembly | X | | \[64\] |
| | Perception of improved safety | X | | \[64\] |
| | Ease of use | X | | \[19,64\] |

Several studies described the need to maintain negative pressure within the device relative to the outside room \[8,31,42,43\]. For ACDs, maintenance of negative pressure requires that the airflow into the device occurs through oxygen or other sources must be exceeded by the exhaust airflow of the ventilation system or suction. Daniel et al. \[31\] found that when airflow out of the device from suction was less than airflow into the device aerosol visibly leaked from the device.

4. Discussion

The COVID-19 pandemic spurred interest in the development of engineering controls, such as ACDs, to prevent environmental contamination and occupational exposures to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In the hierarchy of controls, engineering controls are prioritized over the use of PPE to protect the health and safety HCP and other workers owing to the potential high reliability and effectiveness of engineering controls \[44\], but use of engineering controls is strongly influenced by whether the design and function is acceptable to users. Devices must also meet safety and regulatory requirements, and through increasingly complex testing demonstrate usability for patients and HCP \[45\]. This review identified that ACD performance evaluation methods varied widely between investigators, indicating a lack of consensus about how performance should be evaluated, and about appropriate performance targets.

If an ACD is to be used consistently by HCP, it must result in at least a neutral, if not more positive experience for HCP relative to standard practice with respect to user perception, cognitive demands, posture and biomechanics, among other possible factors. Among the literature reviewed, provider or patient experience was assessed in some way in only a minority of studies \[Table 2\], most of which considered use of the device with endotracheal intubation. With respect to the provider experience metrics assessed measures for intubation \[Table 3\], it is less of a concern that subjective measures were used than that the investigators did not utilize standardized instruments. Standardized instruments like the NASA TLX or the System Usability Scale that can be informative and allow for direct comparison of study results. These types of assessments are a primary subject of research among Human Factors Engineers, and involvement of these experts in device development increases the likelihood of the development of a successful and user-acceptable or even user-friendly device. With respect to posture and biomechanics assessment, when conducted, it was focused on participants’ self-reported ability to perform the necessary tasks or move. While such subjective information is helpful, motion capture studies
that it limits the ability of HCP to perform tasks using their “usual” or “preferred” motions and body positions, as this could have implications for the procedure outcomes due to interference with automaticity while performing the procedure.

Of the four domains, patient experience was the most infrequently assessed, and was evaluated in only 6% of the reviewed studies (Table 2). This finding is not particularly surprising given that only 24% of the reviewed studies utilized field trials that could allow for the evaluation of patient experience. These studies, however, considered patients undergoing intubation and endoscopy, procedures which typically involve sedation. Sedation limits the information that can be

| Reference | Device Design | Procedure | Visual Assessment Surfaces | Visual Assessment HCPs | Visual Assessment Aerosol | Performance Measures |
|-----------|---------------|-----------|----------------------------|------------------------|--------------------------|----------------------|
|           |               |           |                            |                        |                          | Maximum particle concentrations outside device reported, compared with and without aerosol generation. |
|           |               |           |                            |                        |                          | Particle concentrations inside and outside device compared at several time points using t-test. |
|           |               |           |                            |                        |                          | Time to clear the device of aerosol; Particle concentration measured inside and outside device over time. |
|           |               |           |                            |                        |                          | Maximum particle concentrations inside and outside device compared. |
|           |               |           |                            |                        |                          | Particle concentrations measured outside device, compared between device and no device conditions. |
|           |               |           |                            |                        |                          | Droplet size inside device and on participants’ face shields. |
|           |               |           |                            |                        |                          | Tracer concentration measured outside the device, compared between device and no device conditions as percent reduction; Aerosol passing through laser sheet. |
|           |               |           |                            |                        |                          | Particle concentrations inside and outside device compared. |
|           |               |           |                            |                        |                          | Time to clear device of aerosol; top 15% of particle concentrations in each minute outside the device compared between device and no device conditions. |
|           |               |           |                            |                        |                          | Particle concentrations measured in device compared with and without ventilation as percent reduction; time to clearance of 99.9% of particles |
|           |               |           |                            |                        |                          | Mean intensity of pixels in images inside the device over time. |
|           |               |           |                            |                        |                          | Time to clear device of aerosol. |
|           |               |           |                            |                        |                          | Particle concentrations measured inside device with over time, compared with and without ventilation by ANOVA; particle concentrations over time outside device compared to no device. |
|           |               |           |                            |                        |                          | Percent area of gloved hands contaminated; average particle number concentrations outside device compared with and without device. |
|           |               |           |                            |                        |                          | Percent area of gloved hands contaminated and aerosol escaping device. |
|           |               |           |                            |                        |                          | Time to clear the device of aerosol; Particle concentration measured inside and outside device compared. |
|           |               |           |                            |                        |                          | Vapor escaping device; particle concentrations inside and outside device compared. |
|           |               |           |                            |                        |                          | Locations of tracer contamination; vapor escaping device; time to clear device of aerosol |
|           |               |           |                            |                        |                          | Particle concentrations outside the device compared between baseline and with device. |
|           |               |           |                            |                        |                          | Presence on tracer at a priori locations on participants, equipment and surfaces outside the device. |
|           |               |           |                            |                        |                          | Percent surface area contaminated with tracer; tracer concentration. |
|           |               |           |                            |                        |                          | Distance of tracer contamination from surgical site, and on PPE and bodies of participants. |
|           |               |           |                            |                        |                          | Locations of tracer; vapor escaping device |
|           |               |           |                            |                        |                          | Locations of tracer |
|           |               |           |                            |                        |                          | Locations of tracer; tracer aerosol escaping device |
|           |               |           |                            |                        |                          | Detection of noxious odor; vapor escaping device |
|           |               |           |                            |                        |                          | Locations of tracer contamination; vapor escaping device |
|           |               |           |                            |                        |                          | Vapor escaping device |
|           |               |           |                            |                        |                          | Locations of tracer contamination. |
|           |               |           |                            |                        |                          | Percent change in particle concentrations relative to background; aerosol escaping device |
|           |               |           |                            |                        |                          | Score of tracer contamination at different locations. |

Table 4: Aerosol containment testing and performance metrics.
gathered from patients about the experience. ACDs may have much broader applications, including applications in which patients are alert and within the device for prolonged times, such as during patient transport or to provide respiratory isolation. For such applications, additional assessments of the patient experience need to be explored. While there are some instruments available that permit assessment of general patient experience and comfort, these instruments may not be applicable to the specific experience of patients undergoing procedures with the newly developed devices. As a result, simple Likert-type scales that are developed for the specific purpose of assessing patient comfort and experience in these settings would allow more structured and standardized data collection and quantification of patient’s experience.

Among studies that evaluated the impact of devices on the medical procedure, all studied intubation (Table 2), which is a procedure amenable to objective measures of performance that are clinically relevant, such as time to procedure completion and frequency of success on the first attempt (Table 3). Further research is needed to explore the impact of the devices on a broader range of procedures and contexts in which ACDs are anticipated to be used. While other procedures and contexts may be less sensitive to the speed of procedure completion, they may require greater dexterity, visual acuity or other attributes to perform. Impact of a device on procedure performance is closely related to the user experience and patient experience as impediments to timely, successful procedure performance will frustrate users and patients, and potentially diminish the quality of care.

With respect to aerosol containment, a very wide variety of methods and metrics were utilized in the reviewed studies (Table 4). While qualitative assessment provides a general indication of device performance, the approach is inadequate for assessment of containment performance because visual detection of fluorescent material or smoke is less sensitive a method than quantitative methods for fluorescent material or aerosol concentrations. Given that a single pathogen can initiate infection [46], it is necessary to have a robust quantitative measure of containment performance, including variability in performance, so as to enable informed decision making about the performance of the control relative to other strategies, such as respiratory protection. From the perspective of protection of HCP from inhalation exposures to respiratory aerosols, the best metric would be the percent reduction in the time-averaged concentration in the breathing zone of the HCP with the device relative to normal practice without the device, as this metric most directly reflects the exposure reduction achieved by the device, if any. It is not sufficient that the concentration be statistically significantly different at the same location with and without the device [40], nor that the peak concentrations decrease with the device [28,47], because it is the cumulative number of inhaled pathogens that drives the risk of infection [46]. Comparing the aerosol concentration inside the device to outside the device can provide information on leakage [3,34,39,41,48]. but this ratio is not equivalent to the reduction in exposure that the use of the device would provide to the HCP.

Based on the literature reviewed, it is not clear exactly what the aerosol containment performance target should be, other than as high as possible. The standard practice in healthcare to prevent inhalation of airborne-transmissible pathogens in the U.S. has been to wear N95 filtering facepiece respirators (FFRs), which are assumed by the Occupational Safety and Health Administration to reduce exposure by 90% when used in the context of an effective respiratory protection program. Specifically, N95 FFRs have and Assigned Protection Factor (APF) of 10, which means the aerosol concentration inside the facepiece is 1/10th the concentration outside the facepiece; powered air-purifying respirators of the type used in U.S. healthcare facilities have APF = 25, offering a 96% reduction in exposure [49]. Should the aerosol device be intended to decrease reliance on PPE, it would seem that performance should meet or exceed that exposure reduction offered by respiratory protection. Data from the reviewed articles and preliminary testing of similar devices by our research team indicate that such a performance target should be readily attained with a ventilated ACD.

Negative pressure is general principle in ventilation, and is used to control the direction of airflow between two spaces (e.g., from the room into the ACD). Roth et al. [8] utilized the negative pressure guideline of $-2.5 \text{ Pa}$ recommended for AIIRs by the Centers for Disease Control and Prevention as a benchmark for evaluation of their ACD. It’s not clear that this AIIR guideline is appropriate for ACDs. In particular, a lower pressure difference may be adequate. Negative pressure alone, however, is not sufficient to demonstrate aerosol containment, as the pressure gradient can be disrupted by human activities, such as opening or closing ports, allowing aerosols to leak. Thus, while maintaining a target negative pressure may be a reasonable performance goal, the device should also be evaluated to ensure aerosol containment occurs under realistic use conditions.

Though this review did not specifically evaluate the quality of the studies, as the focus was on the types of evaluations performed and their metrics rather than on the specific results obtained, many studies had significant limitations in their experimental design. Types of limitations included: few or no experimental replicates [22,41,50,51], incomplete reporting of experimental replicates [32,40,43], lack of or inappropriate statistical analyses [43,47,48,50], and lack of methodology for some reported results (e.g., anecdotal information, Table 3). While many of the studies reviewed may be considered exploratory, rigorous study designs and methods are required to demonstrate efficacy and effectiveness of ACDs if they are to be incorporated into routine practice as a control system.

While the use of ACDs in U.S. hospitals has diminished with the reduction of COVID-19 hospitalizations and existence of adequate PPE supplies, other applications for ACDs, including patient transport and settings where patient isolation in AIIRs is infeasible, warrant continued research and development of ACDs. Further, the reliance of healthcare facilities on PPE to prevent infection transmission to HCP and susceptible personnel should be reconsidered in light of well-known limitations with PPE compliance and performance. ACDs are an engineering control that can have myriad benefits for infection prevention.

5. Conclusion

ACDs are a novel, promising control strategy to reduce the environmental contamination and the risk of exposure of HCP and patients to infectious respiratory aerosols. As illuminated by this review, assessment of the performance of these devices have been limited in scope and by experimental methods and study design. Beyond aerosol containment performance, device development would benefit from a comprehensive user-centered design approach that incorporates the multiple dimensions of the HCP and patient experience, as well as implementation research studies to explore how these devices can be effectively incorporated into routine clinical practice. Devices that seek to reduce utilization of PPE should reduce HCP exposures to aerosols equivalent to or better than the protection offered by respiratory protection.

Funding information

This study was funded by the Department of Defense, W81XWH2110024. NA received additional support from the Rocky Mountain Center for Occupational and Environmental Health, CDC/NIOSH T42/OH008414, and TD received additional support from AIRFORCE.

Prior abstract publication/presentation

None.
CRediT authorship contribution statement

Rachael M. Jones: Writing – review & editing, Writing – original draft, Supervision, Project administration, Methodology, Funding acquisition, Formal analysis, Data curation, Conceptualization. Niles Andrus: Writing – original draft, Methodology, Formal analysis, Data curation. Thomas Dominguez: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. Jeremy Biggs: Writing – review & editing, Investigation, Formal analysis. Brian Hansen: Writing – review & editing, Project administration, Formal analysis, Data curation. Frank A. Drews: Writing – review & editing, Methodology, Conceptualization.

Declaration of Competing Interest

The authors declare the following interests/personal relationships which may be considered as potential competing interests: Rachael M. Jones reports financial support was provided by US Department of Defense. Niles Andrus reports financial support was provided by National Institute for Occupational Safety and Health. Thomas Dominguez reports financial support was provided by US Airforce.

Acknowledgement

RMJ takes responsibility for the content of the manuscript, including the data and analysis. All authors contributed to the study design and writing of the manuscript. RMJ, NA, TD, JB, BH reviewed the literature, abstracted data and analyzed data. The sponsor had no role in the development of the research or preparation of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ajem.2022.11.007.

References

[1] Siegel J, Rhinehart E, Jackson M, Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control. 2007;35(10):S65–S164.
[2] Profil J, Dubois E, Karakitos D, Hof L. Overview of the user experience for snorkeling mask designs during the COVID-19 pandemic. Healthcare (Basel). 2021;9(2):204.
[3] Brant-Zawadzki G, Ockerse P, Brunson J, Smith J, McRae B, Fonnesbeck A, et al. An aerosol containment and filtration test for intubation during the COVID-19 pandemic. Surg Innov. 2021;28(2):226–30.
[4] Sorello M, Rosenblatt W, Brunson J, Smith J, McRae B, Fonnesbeck A, et al. An aerosol containment and filtration test for intubation during the COVID-19 pandemic. Surg Innov. 2021;28(2):226–30.
[5] Saito T, Asai T. Aerosol box and barrier enclosures for airway management in COVID-19 patients: a scoping review and narrative synthesis. J Br Anesth. 2020;125(6):890–94.
[6] Saito T, Asai T. Aerosol box and barrier enclosures for airway management of patients with COVID-19: a narrative review. J Anesth. 2021;35:384–9.
[7] Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension or scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169:467–73.
[8] Arksey H, Malley LO. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19
[9] Brant-Zawadzki G, Ockerse P, Brunson J, Smith J, McRae B, Fonnesbeck A, et al. Aerosol containment and filtration test for intubation during the COVID-19 pandemic. Surg Innov. 2021;28(2):226–30.
[10] Ibrahim M, Khan E, Babazade R, Simon M, Vadhera R. Comparison of the effectiveness of different barrier enclosure techniques in protection of healthcare workers during tracheal intubation and extubation. APhA Practice. 2020;14(8):e2152–e2.
[11] Cottrell J, Liu J, Le T, Chen J. An operative barrier system for skull base and mastoid surgery: creating a safe operative theatre in the era of COVID-19. J. Otolaryngol Head Neck Surg. 2020;49(1).
[12] Rehm M, Eichler J, Meidert AS, Briegel J. Protecting Health care workers: use of a particle containment chamber. Ann Biomed Eng. 2020:2371–6. Springer.
[13] Colman N, Saldana C, Craig K, Edwards N, McGough J, Mason C, et al. Simulation-based user-centered design: an approach to device development during COVID-19. Pediatric Safety. 2021;6(4):e247–e.
[14] Scott A, Pollock F, Sandefur BJ, Mullen AF, Russi CS, Yalamuri SM. Barrier enclosure for endotracheal intubation in a simulated COVID-19 scenario: A crossover study. West J Emerg Med. 2020;21(5):1080–3.
[15] Lee-Archer P, Boyd D, Du T, Elliott R, Graydon C, Paterson N, et al. A comparison of anatomic protective barrier enclosures for the management of COVID-19 pediatric patients. Paediatr Anaesth. 2021;31(3):323–9.
[16] Colman N, Saldana C, Craig K, Edwards N, McGough J, Mason C, et al. Simulation-based user-centered design: an approach to device development during COVID-19. Pediatric Safety. 2021;6(4):e247–e.
[17] Argüelles J, Laukripa B, Dubois E, Karakitos D, Hof L. Overview of the user experience for snorkeling mask designs during the COVID-19 pandemic. Healthcare (Basel). 2021;9(2):204.
[18] Ibrahim M, Khan E, Babazade R, Simon M, Vadhera R. Comparison of the effectiveness of different barrier enclosure techniques in protection of healthcare workers during tracheal intubation and extubation. APhA Practice. 2020;14(8):e2152–e2.
[19] Cottrell J, Liu J, Le T, Chen J. An operative barrier system for skull base and mastoid surgery: creating a safe operative theatre in the era of COVID-19. J. Otolaryngol Head Neck Surg. 2020;49(1).
[20] Lumleitg S, Inborboon PC. How clean are you really? A simulation study of droplet splash using an acrylic box during cardiopulmonary resuscitation. Simul Healthc J Soc Simul Healthc. 2021;16(2):153–4.
[21] Hsu SH, Lai HY, Zabaneh F, Masud FN. Aerosol containment box: a novel barrier protection for the front line. Emerg Med J. 2020;37(7):400–1.
[22] Lee-Archer P, Boyd D, Du T, Elliott R, Graydon C, Paterson N, et al. A comparison of anatomic protective barrier enclosures for the management of COVID-19 pediatric patients. Paediatr Anaesth. 2021;31(3):323–9.
[23] Colman N, Saldana C, Craig K, Edwards N, McGough J, Mason C, et al. Simulation-based user-centered design: an approach to device development during COVID-19. Pediatric Safety. 2021;6(4):e247–e.
[24] Scott A, Pollock F, Sandefur BJ, Mullen AF, Russi CS, Yalamuri SM. Barrier enclosure for endotracheal intubation in a simulated COVID-19 scenario: A crossover study. West J Emerg Med. 2020;21(5):1080–3.
[25] Chen J, Dubois E, Karakitos D, Hof L. Overview of the user experience for snorkeling mask designs during the COVID-19 pandemic. Healthcare (Basel). 2021;9(2):204.
[26] Ibrahim M, Khan E, Babazade R, Simon M, Vadhera R. Comparison of the effectiveness of different barrier enclosure techniques in protection of healthcare workers during tracheal intubation and extubation. APhA Practice. 2020;14(8):e2152–e2.
[27] Saito T, Asai T. Aerosol box and barrier enclosures for airway management of patients with COVID-19: a narrative review. J Anesth. 2021;35:384–9.
[28] Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension or scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169:467–73.
[29] Arksey H, Malley LO. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8:19–32.
[30] Both BS, Moschella P, Moussavi LE, Matts AS, Flacone RJ, Ashley ND, et al. Development and efficacy testing of a portable negative pressure enclosure for airborne infection containment. JACEP Open. 2021;3:e12656.
[31] Moussavi MS, Hadei M, Majlesi M, Hokep PK, Yarahmadi M, Eman B, et al. Investigating the effect of several factors on concentrations of bioaerosols in a well-ventilated hospital environment. Environ Monit Assess. 2019;191(7):407.
[32] Maloney LM, Yang AH, Princi RA, Eichert AJ, Hébert DR, Kuper TV, et al. A COVID-19 airway management investment with pragmatic efficacy evaluation: The patient particle containment chamber. An Am. J. Resp. Crit. Care Med. 2020;202:2371–6. Springer.
[33] Babazade R, Khan ES, Ibrahim M, Simon M, Vadhera BB. Additional barrier to protect Health care workers during intubation. Anesth Analg: Lippincott Williams and Wilkins. 2020;131(1):e67–8.
[34] Rehm M, Eichler J, Mesiert AS, Briegel J. Protecting Health care workers: use of a body covering transparent sheet during and after intubation of patients with COVID-19. Anesth Analg: Lippincott Williams and Wilkins. 2020;131(2):e111–2.
[35] Motara F, Laher AE, Du Plessis J, Moolia M. The “Intubox”: enhancing frontline healthcare worker Safety during coronavirus disease 2019 (COVID-19). Curren. Paediatr Anaesth. 2020;30(8):e8530.
[36] Fox TH, deBoisblanc BP, Silverblatt M, Lacour A. Negative pressure tent to reduce exposure of Health care workers to SARS-CoV-2 during aerosol generating respiratory therapies. Chest. 2020;158(4):1331.
[37] Kikuchi D, Ariyoshi D, Suzuki Y, Ochiai Y, Ogadiri H, Hayasaka J, et al. Possibility of new shielding device for upper gastrointestinal endoscopy. Endosc Int Open. 2021; 9:1536–41.
[42] Gupta V, Sahani A, Mohan B, Wander G. Negative pressure aerosol containment box: An innovation to reduce COVID-19 infection risk in healthcare workers. J Anaesthesiol Clin Pharmacol. 2020;36(Suppl 1):S14–7.

[43] Issa R, Urbanowicz R, Richebe P, Llaim J, Ferreira Benevides A, Tanouli L. VACuum INtubation (VACiN) box restricts the exhaled air dispersion generated by simulated cough: description and simulation-based tests of an innovative aerosolization protective prototype. J Clin Monit Comput. 2022;36(5):1289–95.

[44] NIOSH. Hierarchy of Controls 2015. Available from: https://www.cdc.gov/niosh/topics/hierarchy/default.html.

[45] Turner M, Duggan L, Gleazerson B, Marshall S. Thinking outside the (acrylic) box: a framework for the local use of custom-made medical devices. Anaesthesia. 2020;75:1566–9.

[46] Haas C, Rose J, Gerba C. Quantitative microbial risk assessment. 2nd ed.. Hoboken, NJ: John Wiley & Sons, Inc; 2014.

[47] Issa R, Urbanowicz R, Richebe P, LBain J, Ferreira Benevides A, Tanouli L. VACuum exhausted isolation locker (VEIL) to reduce inpatient droplet/aerosol transmission during the coronavirus disease 2019 pandemic: a Taiwan experience. Cell Transplant. 2021;30:963689720987527 SAGE Publications Ltd.

[48] Gopesh T, Grant AM, Wen JH, Wen TH, Izuha H, Iseki K. A dome-shaped aerosol box for mitigation of aerosol and particle dispersion during Mastoidectomy relevant to the COVID-19 era. Otol Neurotol. 2020;41(9):1230–9.

[49] Chen JX, Workman AD, Chari DA, Jung DH, Kozin ED, Lee DJ, et al. Demonstration and mitigation of aerosol and particle dispersion during intubation: a protective prototype. J Clin Monit Comput. 2022;36(5):1289–95.

[50] Yamamoto S, Nakayama M, Tsubochi H, Endo S. A novel protective barrier enclosure for performing bronchoscopy. Respir Investig. 2021;59(2):260–2.

[51] Lederer W, Isser M. Barrier resuscitation by lay rescuers during COVID-19 pandemic. MedHypotheses. 2021;154:110648.

[52] Nayak S, Reddy YP, Behera S, Adish TS, Satyanarayana D. Virus containment box for percutaneous endoscopic gastrostomy tube placement during coronavirus disease 2019 pandemic. BMJ Case Rep. 2020;13(7).

[53] Rose P, Veall J, Chima N, Vowels E, Chitnis S, Flexman A, et al. A comparison of overhead transparent plastic barrier with powered suction technique intended to limit coronavirus disease 2019 aerosols spread during fiber-optic intubation and throughout the surgery. Surg Neurol Int. 2020;11.

[54] Gonzalez-Ciccarelli LF, Nilson J, Hojman HM, Sekhar P, Velez M, Quraishi SA. Continuous negative pressure operative field barrier for combined open tracheostomy and percutaneous endoscopic gastrostomy tube placement during coronavirus disease 2019. A&A Practice. 2020;14(14) e01371-e.

[55] Leow VM, Mohamad IS, Subramaniam M. Use of aerosol protective barrier in a patient with impending cholangitis and unknown COVID-19 status undergoing emergency ERCP during COVID-19 pandemic. BMJ Case Rep. 2020;13(7).

[56] Luk NN, Yang VL, Tsai PB. Application of plastic sheet barrier and video intubating stylet to protect tracheal intubators during coronavirus disease 2019 pandemic: a Singapore experience. Anaesthesia. 2020;75:1566–9.

[57] Als Karam K, Hota P, Mora SJ, Lowell A, McKay K, Xian X, et al. Development of a new aerosol barrier mask for mitigation of spread of SARS-CoV-2 and other infectious pathogens. Respir Med. 2021;181.

[58] Nair N, Sharma V, Dixit A, Goyal S, Dixit SG, Goyal A, et al. Barrier enclosure in trachecotomy: a protective box for healthcare workers during the coronavirus disease 2019 pandemic. J Laryngol Otol. 2022;136:265–7.

[59] Yamamoto S, Nakayama M, Tsubochi H, Endo S. A novel protective barrier enclosure for performing bronchoscopy. Respir Investig. 2021;59(2):260–2.

[60] Enos J, Cubillos J, Ding Y, Cherry R, Armstrong K. Barrier enclosure in trachecotomy: a protective box for healthcare workers during the coronavirus disease 2019 pandemic. J Laryngol Otol. 2022;136:265–7.

[61] Garzona-Navas A, Sajgalik P, Csecs I, Askew J, Lopez-Himenez F, Niven AS, et al. Mitigation of aerosols generated during exercise testing with a portable high-efficiency particulate air filter with fume hood. Chest. 2021;160(4):1388–96.

[62] Lederer W, Isser M. Barrier resuscitation by lay rescuers during COVID-19 pandemic. MedHypotheses. 2021;154:110648.

[63] Nayak S, Reddy YP, Behera S, Adish TS, Satyanarayana D. Virus containment box for percutaneous endoscopic gastrostomy tube placement during coronavirus disease 2019 pandemic. BMJ Case Rep. 2020;13(7).

[64] Querney J, Cubillos J, Ding Y, Cherry R, Armstrong K. Barrier enclosure in trachecotomy: a protective box for healthcare workers during the coronavirus disease 2019 pandemic. J Laryngol Otol. 2022;136:265–7.

[65] Lederer W, Isser M. Barrier resuscitation by lay rescuers during COVID-19 pandemic. MedHypotheses. 2021;154:110648.